Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach-Reference-Cited by-同舟云学术

Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach

Published:2006-06-21 Issue:7 Volume:15 Page:795-804
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Koutsilieris Michael,Bogdanos John,Milathianakis Constantine,Dimopoulos Peter,Dimopoulos Theodoros,Karamanolakis Dimitrios,Halapas Antonis,Tenta Roxane,Katopodis Haralampos,Papageorgiou Effie,Pitulis Nea,Pissimissis Nikos,Lembessis Peter,Sourla Antigone

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/13543784.15.7.795

Reference79 articles.

1. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

2. Mechanisms of Tumor Metastasis to the Bone: Challenges and Opportunities

3. Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis

4. Matrix Metalloproteinase Activity, Bone Matrix Turnover, and Tumor Cell Proliferation in Prostate Cancer Bone Metastasis

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate cancer;Frontiers in Cell and Developmental Biology;2022-07-22

2. Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis;Frontiers in Pharmacology;2018-11-28

3. Anakoinosis: kommunikative Netzwerke im Tumorsystem reprogrammieren;Im Focus Onkologie;2017-12

4. Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies;Critical Reviews in Oncology/Hematology;2014-10

5. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer;Expert Opinion on Investigational Drugs;2013-09-12